Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

Il Consiglio Di Amministrazione approva la Posizione Finanziaria Netta relativa al Terzo Trimestre 2023

more details

The Board of Directors approves the net financial position for the third quarter of 2023

more details

Philogen to attend the Annual Meeting Cancéropôle Grand Sud-Ouest in Arcachon on November 22-24, 2023.

Prof. Dario Neri, PhD, (CEO and CSO of Philogen) is giving a presentation entitled “From encoded combinatorial libraries to clinical-stage targeted therapeutics”....

23 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details

16 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details

Nidlegy™ ha raggiunto positivamente l’obiettivo primario dello studio di Fase III PIVOTAL in pazienti con melanoma localmente avanzato completamente resecabile (Price Sensitive)

See more details

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective in patients with locally advanced fully resectable melanoma (Price Sensitive)

See more details

09 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details

02 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2023 (Price sensitive) – Courtesy English Translation

more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions